Product Overview
[Drug Name]
Generic Name: Levoamlodipine Besylate Tablets
Trade Name: Hong Fu Ri Levoamlodipine Besylate Tablets, 2.5mg x 28 Tablets
Pinyin Code: HongFuRi BenHuangSuanZuoAnLvDiPingPian, 2.5mg x 28 Tablets
[Main Ingredient]
The main ingredient and its chemical name are: (-)3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate benzenesulfonate
[Indications/Main Functions]
1. Hypertension (used alone or in combination with other medications)
2. Angina pectoris: especially spontaneous angina (used alone or in combination with other medications)
[Precautions]
1. Angina pectoris and/or myocardial infarction: Rare. Patients with severe obstructive coronary artery disease may experience an increase in the frequency, duration, and/or severity of angina attacks, or the development of acute myocardial infarction, when starting or increasing the dose of calcium channel blockers. The mechanism is unknown. 2. Hypotension: Because this drug gradually exerts its vasodilatory effect, acute hypotension is generally rare with oral administration. However, caution should be exercised when using this drug in combination with other peripheral vasodilators, especially in patients with severe aortic stenosis. 3. Patients with Heart Failure: Calcium channel blockers should be used with caution in patients with heart failure. 4. Patients with Hepatic Impairment: This drug should be used with caution in patients with severe hepatic impairment.
[Drug Interactions]
Allergy to dihydropyridine calcium channel blockers.
[Pediatric Use]
No data are available for the use of this drug in children.
[Elderly Use]
Elderly patients can use the normal dose. However, it is advisable to start with a lower dose and then gradually increase it.
[Use During Pregnancy and Breastfeeding]
This product is recommended only when there are no safer alternatives and the disease itself poses a greater risk to mother and child.
[Specifications]
2.5mg x 14 tablets x 2 boxes
[Dosage and Administration]
The usual starting oral dose is 5mg once daily, with a maximum of 10mg once daily. For thin individuals, those with frail constitutions, elderly patients, or those with impaired liver function, start with 2.5mg once daily. Patients taking other antihypertensive medications should also start with this dose. The dosage should be adjusted based on individual needs, with a minimum adjustment period of 7-14 days to allow the physician to fully assess the patient's response. However, faster adjustment may be possible if clinically warranted. The recommended dose for the treatment of angina pectoris is 5-10mg; a reduced dose is required for elderly patients or those with impaired liver function.
[Adverse Reactions]
This product is well tolerated. 1. Less common side effects include headache, edema, fatigue, insomnia, nausea, abdominal pain, flushing, palpitations, and dizziness. 2. Extremely rare side effects include itching, rash, dyspnea, weakness, muscle cramps, and indigestion. 3. Similar to other calcium channel blockers, there have been rare reports of adverse reactions such as myocardial infarction and chest pain, and these adverse reactions cannot be clearly distinguished from the patient's underlying medical conditions. 4. No abnormal laboratory parameters associated with this drug have been found.
[Contraindications]
Allergic reaction to dihydropyridine calcium channel blockers.
[Pharmacology and Toxicology]
Amlodipine besylate is a dihydropyridine calcium channel blocker (calcium ion antagonist or slow-channel blocker). The contraction of cardiac and smooth muscle depends on the entry of extracellular calcium ions into cells through specific ion channels. This drug selectively inhibits the transmembrane entry of calcium ions into smooth muscle cells and cardiac muscle cells, with a greater effect on smooth muscle than cardiac muscle. Its interaction with calcium channels is determined by the progressive rate of binding and dissociation from receptor sites, resulting in a gradual onset of pharmacological action. This product is a peripheral arterial dilator that acts directly on vascular smooth muscle, reducing peripheral vascular resistance and thus lowering blood pressure. At therapeutic doses, negative inotropic effects can be observed in in vitro experiments, but not in whole animal experiments. This product does not affect plasma calcium concentration. Fifteen randomized double-blind, placebo-controlled clinical trials have confirmed the antihypertensive effect of this product.
